Skip to main
VTVT

vTv Therapeutics (VTVT) Stock Forecast & Price Target

vTv Therapeutics (VTVT) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

vTv Therapeutics is well-positioned in the growing market for diabetes treatments, with its promising lead drug candidate Cadi and a strong pipeline of other potential treatments. The company has a clear strategy, backed by experienced leadership, to develop and commercialize these treatments through strategic partnerships and collaborations. Additionally, the company has a solid financial foundation, with a healthy balance sheet and positive cash flow, positioning it for long-term success in the competitive pharmaceutical industry.

Bears say

vTv Therapeutics is a late-stage biopharmaceutical company with a focus on developing drug candidates for chronic diseases, specifically diabetes. Its pipeline consists of various small-molecule candidates, with the lead drug cadisegliatin showing promising results in Phase 2 trials. However, the company faces typical risks of the biotechnology sector, including clinical and regulatory challenges. Additionally, vTv will need to raise additional capital to advance cadisegliatin towards approval, and success is not guaranteed as the drug has not yet been approved for type 1 diabetes. The potential for positive results in the MENA-based T2D trial provides some hope, but the outcome is uncertain. Given these challenges, as well as the competitive landscape in the diabetes space, the financial analyst has a negative outlook on vTv Therapeutics' stock.

vTv Therapeutics (VTVT) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of vTv Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About vTv Therapeutics (VTVT) Forecast

Analysts have given vTv Therapeutics (VTVT) a Strong Buy based on their latest research and market trends.

According to 5 analysts, vTv Therapeutics (VTVT) has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

vTv Therapeutics (VTVT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.